Background: The glycaemic control among people with diabetes in India is very poor. This study evaluated the effectiveness an iPDM (integrated personalised self-management) in changing health behavior to improve blood glucose levels.

Methods: We used data from 883 participants (Average = 45.41 years; 72.71% male) who were using Accu-Chek® Active in conjunction with Wellthy Care™ digital therapeutic (WC DTx). The participants had to log the blood sugar values into the app manually. The WC DTx, developed in lines with AADE7 and RSSDI guidelines, includes skill-development through self-management education, and real time feedback and coaching through artificial intelligence (AI).

Results: The users were on the combination of the Accu-Chek® Active blood sugar monitor and its companion WC DTx for an average of 30.87 days. There was a significant difference between the mean first and last logged fasting blood sugar (FBS) (149.33 mg/dl vs. 132.83 mg/dl, p = 0.0013) and random blood sugar (202.20 mg/dl vs. 169.79 mg/dl, p = 0.004) values. The average per-user app interaction was 8.12 instances. A total of 2184 blood glucose measurements were logged with an average of 2.29 measurements per user. There was a step-wise decrease in FBS as the app engagement increased. The lowest tertile of app engagers reduced their FBS by 20.99 mg/dl (p=0.086), the middle tertile of app engagers reduced their FBS 23.98 mg/dl (p=0.038), and those in the highest tertile of app engagers reduced their FBS by 25.36 mg/dl (p=0.016). The reduction in random blood sugar in the highest level of app engagers was significant (p=0.04) than the reduction in the lowest (p=0.144) and middle tertile (0.296) of app engagers.

Conclusion: iPDM using Accu-Chek® Active along with Wellthy Care™ as a companion therapeutic, can help people with diabetes in India to improve self-management skills and overall blood sugar levels.

Disclosure

R. Chawla: None. A. Krishnakumar: Employee; Self; Wellthy Therapeutics. V. Khatry: Employee; Self; Roche Diabetes Care. A. Shah: Stock/Shareholder; Self; Wellthy Therapeutics. S. Joshi: None. S.S. Shaikh: None. T. Lathia: None. H. Thacker: None. K. Samudra: None. V. Mattoo: Consultant; Self; Wellthy Therapeutics.

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.